Rationale: Although inflammation and infection are key disease drivers in bronchiectasis,
few studies have integrated host inflammatory and microbiome data to guide precision …

Bronchiectasis is increasing in prevalence worldwide, yet current treatments available are
limited to those alleviating symptoms and reducing exacerbations. The pathogenesis of the …

Background Infection is a key component of bronchiectasis pathophysiology.
Characterisation of the microbiome offers a higher degree of sensitivity and resolution than …

Bronchiectasis is a highly complex entity that can be very challenging to investigate and
manage. Patients are diverse in their aetiology, symptoms, risk of complications and …

Background Molecular-based diagnostic techniques can compensate for the inherent
limitations of culture-based microbiology and provide a more comprehensive description of …

Purpose Bronchiectasis is predominantly marked by neutrophilic inflammation. The
relevance of type 2 biomarkers in disease severity and exacerbation risk is poorly …

Background Systemic inflammation in bronchiectasis is poorly studied in relation to
aetiology and severity. We hypothesized that molecular patterns of inflammation may define …

Patients with bronchiectasis present with cough and recurrent respiratory infections and
experience pulmonary exacerbations necessitating antimicrobial therapy including …

Rationale: Although airway microbiota composition correlates with clinical measures in non–
cystic fibrosis bronchiectasis, these data are unlikely to provide useful prognostic information …

Bronchiectasis is marked by bronchial dilatation, recurrent infections and significant
morbidity, underpinned by a complex interplay between microbial dysbiosis and immune …